In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated mycobactenum avium complex strains in Japan

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4071-4076

  Kohno, Yoshihisa ^a   Ohno, Hideaki ^a   Miyazaki, Yoshitsugu ^a   Higashiyama, Yasuhito ^a   Yanagihara, Katsunori ^a   Hirakata, Yoichi ^a   Fukushima, Kiyoyasu ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; JAPAN; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANIMALS; AZA COMPOUNDS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; JAPAN; LIVER; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; OFLOXACIN; QUINOLINES; SPLEEN;

EID: 35848940755     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00410-07     Document Type: Article

References (20)

1. Alvirez-Freites, E. J., J. L. Carter, and M. H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
2. American Thoracic Society. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 156:S1-S25.
3. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Petrofsky, P. Aralar, M. Wu, and L. S. Young. 2001. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45:217-222.
4. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Petrofsky, and L. S. Young. 1994. Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob. Agents Chemother. 38:2717-2721.
5. Bermudez, L. E., C. B. Inderlied, P. Kolonoski, M. Wu, L. Barbara-Burnham, and L. S. Young. 1996. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrob. Agents Chemother. 40:546-551.
6. Field, S. K., D. Fisher, and R. L. Cowie. 2004. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 126:566-581.
7. Gradelski, E., B. Kolek, D. P. Bonner, L. Valera, B. Minassian, and J. Fung-Tomc. 2001. Activity of gatifioxacin and ciprofloxacin in combination with other antimicrobial agents. Int. J. Antimicrob. Agents 17:103-107.
8. Hewlett, P. S. 1969. Measurement of the potencies of drug mixtures. Biometrics 25:477-487.
9. Inderlied, C. B., C. A. Kemper, and L. E. Bermudez. 1993. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6:266-310.
10. Jacobs, M. R. 2004. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr. Pharm. Des. 10:3213-3220.
11. Katou, K., A. Nakamura, T. Kato, K. Tonegawa, T. Kutsuna, T. Niwa, H. Morita, and M. Itoh. 2005. Combined effects of panipenem and aminoglycosides on methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in vitro. Chemotherapy 51:387-391.
12. Kobashi, Y., and T. Matsushima. 2004. Comparison of clinical features in patients with pulmonary Mycobacterium avium complex (MAC) disease treated before and after proposal for guidelines. J. Infect. Chemother. 10: 25-30.
13. Kobashi, Y., and T. Matsushima. 2003. The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease. Intern. Med. 42:670-675.
14. Leysen, D. C., A. Haemers, and S. R. Pattyn. 1989. Mycobacteria and the new quinolones. Antimicrob. Agents Chemother. 33:1-5.
15. Perichon, B., and P. Courvalin. 2006. Synergism between β-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrob. Agents Chemother. 50:3622-3630.
16. Rodriguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifioxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
17. Rodriguez Diaz, J. C., M. Lopez, M. Ruiz, and G. Royo. 2003. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int. J. Antimicrob. Agents 21:585-588.
18. Struillou, L., Y. Cohen, N. Lounis, G. Bertrand, J. Grosset, J. L. Vilde, J. J. Pocidalo, and C. Perronne. 1995. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob. Agents Chemother. 39:878-881.
19. Tomioka, H., C. Sano, K. Sato, and T. Shimizu. 2002. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Int. J. Antimicrob. Agents 19:139-145.
20. Tsukamura, M., N. Kita, H. Shimoide, S. Nagasawa, H. Arakawa, A. Kuze, A. Shinoda, N. Takasawa, H. Kamimura, R. Wada, et al. 1985. Studies on lung disease due to non-tuberculous mycobacteria in Japan (report of the year 1983 of the Mycobacteriosis Research Group of the Japanese National Chest Hospitals). Kekkaku 60:299-308.